Steven Coutre

Hematologist, Medical oncologist, Leukemia specialist, Multiple myeloma specialist

Professor of Medicine (Hematology) at the Stanford University Medical Center
4.8 out of 5
223 Patient Ratings
11 Patient Comments

Cancer Center

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic » Getting Here » Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic » Getting Here » Make An Appointment

Professional Education

Fellowship: Stanford University School of Medicine (1992) CA

Residency: Yale - New Haven Hospital (1989) CT

Internship: Yale - New Haven Hospital (1987) CT

Medical Education: Stanford University School of Medicine (1986) CA

BS, Northwestern University, Biochemistry (1981)

MD, Stanford University, Medicine (1986)

Internship/Residency, Yale-New Haven Hospital, Internal Medicine (1989)

Fellowship, Stanford University, Hematology (1992)

Honors & Awards

Timothy F. Beckett, Jr. Award for Excellence in Clinical Teaching, Stanford University (1990)

Bernard Cohen Postdoctoral Fellowship, Stanford University (1991)

Division Teaching Award, Stanford University (2002)

Administrative Appointments

Vice Chair, Clinical Affairs, Department of Medicine (2011 - Present)

Disease Management Group Leader-Hematology, Stanford Hospital and Clinics (2010 - Present)

Acute Myeloid Leukemia Panel, National Comprehensive Cancer Network (1998 - Present)

Acute Lymphoblastic Leukemia Panel, National Comprehensive Cancer Network (2012 - Present)

Vice Chair, Leukemia Committee, Southwest Oncology Group (1996 - Present)

Director of Hematology Clinic, Stanford University (1996 - Present)

Associate Director, Internal Medicine Residency program, Stanford University (2009 - 2011)

Patient Ratings and Comments

4.9

Friendliness

4.8

Recommended to others

4.8

Explanations

4.8

Listens

4.8

Includes you in decisions

4.9

Clear Communication

4.9

Confidence in your doctor

4.2

Wait times

SHC Patient, Oct 2014

I am new to and would have liked more answers that I didn't know the question.

SHC Patient, Oct 2014

Dr. Coutre is very knowledgeable & explains well, extremely experienced & educated.

SHC Patient, Aug 2014

Dr. Coutre was excellent as a provider and an expert on my cancer.

SHC Patient, Aug 2014

Dr. Coutre, the best.

View all 11 patient comments

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., & Hillmen, P. (2014). Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England journal of medicine, 371(3), 213-223.

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., & O'Brien, S. M. (2014). Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England journal of medicine, 370(11), 997-1007.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
O'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., & Byrd, J. C. (2014). Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. LANCET ONCOLOGY, 15(1), 48-58.

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., & O'Brien, S. (2013). Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 369(1), 32-42.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
Kantarjian, H., Faderl, S., Garcia-Manero, G., Luger, S., Venugopal, P., & Plunkett, W. (2012). Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. LANCET ONCOLOGY, 13(11), 1096-1104.

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., & Pastan, I. (2012). Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 30(15), 1822-1828.

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
Powell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., & Larson, R. A. (2010). Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. BLOOD, 116(19), 3751-3757.

Optimizing therapy for acute myeloid leukemia.
Kohrt, H. E., & Coutre, S. E. (2008). Optimizing therapy for acute myeloid leukemia. Journal of the National Comprehensive Cancer Network , 6(10), 1003-1016.

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., & Coutre, S. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. BLOOD, 110(7), 2309-2315.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
DeAngelo, D. J., Yu, D., Johnson, J. L., Coutre, S. E., Stone, R. M., & Larson, R. A. (2007). Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. BLOOD, 109(12), 5136-5142.

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., & Baccarani, M. (2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. BLOOD, 109(8), 3207-3213.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., & Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865-2870.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in cancer biology, 14(4), 307-315.

The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutre, S. E. (2004). The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. BLOOD, 103(8), 2879-2891.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., & Gilliland, D. G. (2003). A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. NEW ENGLAND JOURNAL OF MEDICINE, 348(13), 1201-1214.

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Coutre, S. E., Othus, M., Powell, B., Willman, C. L., Stock, W., & Appelbaum, F. R. (2014). Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. BRITISH JOURNAL OF HAEMATOLOGY, 165(4), 497-503.

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Advani, A. S., McDonough, S., Coutre, S., Wood, B., Radich, J., & Appelbaum, F. R. (2014). SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British journal of haematology, 165(4), 504-509.

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
Coutre, S. E., Othus, M., Powell, B., Willman, C. L., Stock, W., & Appelbaum, F. R. (2014). Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. British journal of haematology, 165(4), 497-503.

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia
Advani, A. S., McDonough, S., Coutre, S., Wood, B., Radich, J., & Appelbaum, F. R. (2014). SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 165(4), 504-509.

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., & O'Brien, S. M. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 370(11), 997-1007.

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
Nand, S., Othus, M., Godwin, J. E., Willman, C. L., Norwood, T. H., & Appelbaum, F. R. (2013). A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. BLOOD, 122(20), 3432-3439.

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.
Nand, S., Othus, M., Godwin, J. E., Willman, C. L., Norwood, T. H., & Appelbaum, F. R. (2013). A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood, 122(20), 3432-3439.

Acute myeloid leukemia, version 2.2013.
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., & Naganuma, M. (2013). Acute myeloid leukemia, version 2.2013. Journal of the National Comprehensive Cancer Network , 11(9), 1047-1055.

Acute Myeloid Leukemia, Version 2.2013 Featured Updates to the NCCN Guidelines
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., & Naganuma, M. (2013). Acute Myeloid Leukemia, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(9), 1047-1055.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., & Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. HAEMATOLOGICA, 98(4), 591-596.

Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter? Results From a Prospective Randomized Trial
Lamanna, N., Heffner, L. T., Kalaycio, M., Schiller, G., Coutre, S., & Weiss, M. A. (2013). Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter? Results From a Prospective Randomized Trial. CANCER, 119(6), 1186-1194.

High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., & Kantarjian, H. (2013). High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 31(6), 676-683.

A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21).

Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).

Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., & Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957-960.

Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Arber, D. A., & Gregory, K. M. (2012). Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 984-1021.

Acute Lymphoblastic Leukemia
Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Bellam, N., & Gregory, K. M. (2012). Acute Lymphoblastic Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(7), 858-913.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., & Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893-901.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Wendtner, C.-M., Hillmen, P., Mahadevan, D., Buehler, A., Uharek, L., & Chanan-Khan, A. A. (2012). Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 53(3), 417-423.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133-136.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., & Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30-37.

Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45-50.

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., & Smith, B. D. (2011). Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. BLOOD, 117(12), 3294-3301.

Acute Myeloid Leukemia
O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Coutre, S. E., & Wang, E. S. (2011). Acute Myeloid Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(3), 280-317.

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., & Levy, R. (2011). CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. BLOOD, 117(8), 2423-2432.

Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities
Ho, D. Y., Lin, M., Schaenman, J., Rosso, F., Leung, A. Nc., & Montoya, J. G. (2011). Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities. MYCOSES, 54(1), 59-70.

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia
Advani, A. S., Gundacker, H. M., Sala-Torra, O., Radich, J. P., Lai, R., & Appelbaum, F. R. (2010). Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 151(5), 430-434.

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
Wendtner, C., Hillmen, P., Mahadevan, D., Stilgenbauer, S., Uharek, L., & Chanan-Khan, A. A. (2010). Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). BLOOD, 116(21), 591-592.

A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., & Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347-1347.

Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., & Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357-1358.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.

Classification and Risk Stratification for Acute Promyelocytic Leukemia
Coutre, S. (2010). Classification and Risk Stratification for Acute Promyelocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 10, S127-S129.

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Tong, W.-G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., & Wierda, W. G. (2010). Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. JOURNAL OF CLINICAL ONCOLOGY, 28(18), 3015-3022.

Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420-421.

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., & Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646-647.

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
Chen, C., Reece, D. E., Siegel, D., Niesvizky, R., Boccia, R. V., & Rajkumar, V. (2009). Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 146(2), 164-170.

Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., & Zehnder, J. (2009). Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
Cortes, J., Kim, D.-W., Raffoux, E., Martinelli, G., Ritchie, E., & Talpaz, M. (2008). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. LEUKEMIA, 22(12), 2176-2183.

Acute myeloid leukemia.
O'Donnell, M. R., Appelbaum, F. R., Coutre, S. E., Damon, L. E., Erba, H. P., & White, F. L. (2008). Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network , 6(10), 962-993.

Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer
Hamilton, C. A., Kao, J. M., Coutre, S. E., & Teng, N. Nh. (2007). Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer. GYNECOLOGIC ONCOLOGY, 106(2), 423-426.

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
Rawstron, A. C., Villamor, N., Ritgen, M., Boettcher, S., Ghia, P., & Hillmen, P. (2007). International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. LEUKEMIA, 21(5), 956-964.

Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval
Moayeri, S. E., Coutre, S. E., Ramirez, E. J., & Westphal, L. M. (2007). Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 196(4).

Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
Nabhan, C., Coutre, S., & Hillmen, P. (2007). Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. BRITISH JOURNAL OF HAEMATOLOGY, 136(3), 379-392.

Refractory hematuria from amyloidosis successfully treated by splenectomy
Ma, J. F., Coutre, S. E., Curet, M. J., & Brooks, J. D. (2006). Refractory hematuria from amyloidosis successfully treated by splenectomy. UROLOGY, 67(5).

Acute myeloid leukemia clinical practice guidelines in oncology.
O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Byrd, J. C., Coutre, S. E., & Tallman, M. S. (2006). Acute myeloid leukemia clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(1), 16-36.

The evolving role of alemtuzumab in management of patients with CLL
Faderl, S., Coutre, S., Byrd, J. C., Dearden, C., Denes, A., & Rai, K. (2005). The evolving role of alemtuzumab in management of patients with CLL. LEUKEMIA, 19(12), 2147-2152.

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
McCullough, J., Vesole, D. H., Benjamin, R. J., Slichter, S. J., Pineda, A., & Conlan, M. G. (2004). Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. BLOOD, 104(5), 1534-1541.

Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia
Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., & Hillmen, P. (2004). Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia. CLINICAL LYMPHOMA, 4(4), 220-227.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate
Coutre, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. SEMINARS IN CANCER BIOLOGY, 14(1), 23-31.

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR alpha-induced myeloproliferative disease
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., & Gilliland, D. G. (2003). PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR alpha-induced myeloproliferative disease. CANCER CELL, 3(5), 459-469.

T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao, T. M., & Coutre, S. E. (2003). T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H). Hematology , 8(1), 1-6.

Management of advanced chronic lymphocytic leukemia.
Cao, T. M., & Coutre, S. E. (2003). Management of advanced chronic lymphocytic leukemia. Current hematology reports, 2(1), 65-72.

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia
Nguyen, D. D., Cao, T. M., Dugan, K., Starcher, S. A., Fechter, R. L., & Coutre, S. E. (2002). Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. CLINICAL LYMPHOMA, 3(2), 105-110.

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., & Druker, B. J. (2002). Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. BLOOD, 99(10), 3530-3539.

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
Keating, M. J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., & Herait, P. (2002). Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. JOURNAL OF CLINICAL ONCOLOGY, 20(1), 205-213.

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., & Warrell, R. P. (2001). United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. JOURNAL OF CLINICAL ONCOLOGY, 19(18), 3852-3860.

NCCN Practice Guidelines for acute myelogenous leukemia
O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Carabasi, M. H., Coutre, S. E., & Tallman, M. S. (2000). NCCN Practice Guidelines for acute myelogenous leukemia. ONCOLOGY-NEW YORK, 14(11A), 53-61.

CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING
Gibbs, C. S., Coutre, S. E., Tsiang, M., Li, W. X., Jain, A. K., & Leung, L. Lk. (1995). CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING. NATURE, 378(6555), 413-416.

4.8 out of 5
223 Patient Ratings
11 Patient Comments

SHC Patient, Oct 2014

I am new to and would have liked more answers that I didn't know the question.

SHC Patient, Oct 2014

Dr. Coutre is very knowledgeable & explains well, extremely experienced & educated.

SHC Patient, Aug 2014

Dr. Coutre was excellent as a provider and an expert on my cancer.

SHC Patient, Aug 2014

Dr. Coutre, the best.

SHC Patient, Jun 2014

Absolutely would recommend Dr. Coutre - He & SCC are the best thing about my disorders I feel very blessed to be able to receive care here.

SHC Patient, May 2014

Dr. Coutre is a strong, friendly and professional HC provider.

SHC Patient, May 2014

Dr. Coutre has been a great provider.

SHC Patient, Apr 2014

Resident not informed about my situation, was not prepared.

SHC Patient, Apr 2014

Dr. Courte was very thorough in his explanation of my illness.

SHC Patient, Mar 2014

Dr. Coutre & the fellow were very compassionate, very clear in their explanations!

SHC Patient, Mar 2014

Best doctor, best care, best facility.